Cutler Group LP Neurocrine Biosciences Inc Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	BUY	$106.72 - $127.06 $522,928 - $622,594	4,900 New	4,900 $33,000
Q4 2019 Feb 06, 2020	BUY	$86.8 - $118.57 $217,000 - $296,425	2,500 Added 100.0%	5,000 $3,000
Q3 2019 Oct 28, 2019	SELL	$83.82 - $101.5 $293,370 - $355,250	-3,500 Reduced 58.33%	2,500 $0
Q1 2019 May 10, 2019	BUY	$69.31 - $91.53 $6,931 - $9,153	100 Added 1.69%	6,000 $47,000
Q4 2018 Feb 05, 2019	BUY	$68.32 - $124.36 $61,487 - $111,924	900 Added 18.0%	5,900 $18,000
Q3 2018 Nov 07, 2018	SELL	$98.88 - $125.85 $1.62 Million - $2.06 Million	-16,400 Reduced 76.64%	5,000 $44,000
Q2 2018 Aug 10, 2018	SELL	$75.3 - $105.99 $82,830 - $116,589	-1,100 Reduced 4.89%	21,400 $170,000
Q1 2018 May 11, 2018	BUY	$75.88 - $92.43 $1.21 Million - $1.48 Million	16,000 Added 246.15%	22,500 $78,000
Q4 2017 Jan 17, 2018	SELL	$58.53 - $77.59 $70,236 - $93,108	-1,200 Reduced 15.58%	6,500 $119,000
Q3 2017 Oct 17, 2017	BUY	$47.97 - $61.28 $369,369 - $471,856	7,700	7,700 $83,000

632

93.9M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.